Background: This study aims to compare the effects of single inhaler triple therapy comprised of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and longacting muscarinic receptor antagonists (LAMAs) with dual therapies comprised of either LABA/LAMA, ICS/LABA or separate ICS/LABA plus LAMA triple therapy. Methods: The Pubmed, Embase, and Cochrane databases were searched up to October 31st 2018. Only randomized controlled trials were included in the meta-analysis. The primary outcome was the rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations. Results: Seven studies fulfilling the inclusion criteria were included in the meta-analysis. Single inhaler triple therapy was associated with a significantly lower risk of COPD exacerbation compared with LABA/LAMA (rate ratio, 0.69; 95% confidence interval [CI] 0.55 to 0.87, I 2 =85%), and ICS/LABA (rate ratio, 0.81; 95% CI 0.73 to 0.89, I 2 =29%) dual therapy.
Introduction
Triple inhaled therapy comprised of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs), has been recommended for chronic obstructive pulmonary disease (COPD) patients who still have clinically significant symptoms following the use of a dual inhaler with LABA plus LAMA or LABA plus ICS, and those who have a higher risk of exacerbation. 1, 2 Traditionally, patients receiving triple therapy need to use multiple inhalers several times a day. Typically, these patients used combined ICS/LABA in one inhaler and LAMA in another inhaler, and these inhalers may be of different types and designs. [3] [4] [5] [6] [7] [8] [9] [10] This may lead to incorrect use of the inhalers and affect the patient's adherence to treatment. Recently, a single inhaler containing triple therapy ICS, LABA, and LAMA has been developed as a more practical alternative, which may improve therapy compliance. At present, there are three different formulas for single inhaler triple therapy, including fluticasone furoate (FF)/ umeclidinium (UMEC)/vilanterol (VI) in a once daily dry powder inhaler formulation (Trelegy Ellipta; GSK, Uxbridge, UK), extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FOR)/glycopyrronium bromide (GB) in a twice daily extra fine particle pressurized metered dose inhaler (pMDI) formulation (Trimbow; Chiesi, Parma, Italy), and budesonide (BUD)/GB/FOR in a co-suspension pMDI formulation (Aerosphere; Luton, UK, not approved).
Recently, several randomized controlled trials (RCTs) have shown that extrafine BDP/FOR/GB therapy could be associated was a lower rate of moderate-to-severe COPD exacerbations, [11] [12] [13] as well as improved lung function and
health-related quality of life 13 compared with other treatment options. Bremner et al, 14 showed that FF/UMEC/VI findings regarding the efficacy of single inhaler triple therapy for COPD patients, there were some differences among them in terms of study design, study subjects, the treatments compared, and the outcome analysis. A metaanalysis pooling the results of previous trials would be helpful to clarify these issues. Therefore, the current study performed a systematic review and meta-analysis of previous literature to determine the effect of single inhaler triple therapy with ICS/LABA/LAMA on the risk of exacerbation and other relevant outcomes in patients with COPD. 
Methods

Study search and selection
Definitions and outcomes
The primary outcome of the current study was the risk of moderate or severe COPD exacerbation. Secondary outcomes included changes in lung function from baseline in trough Forced expiratory volume in 1 s (FEV 1 ), the change from baseline in St. George's Respiratory Questionnaire (SGRQ), risk of COPD hospitalization, respiratory-and COPD-mortality and the risk of adverse events.
Statistical analysis
When two or more comparable studies (similar population characteristics, interventions, and outcome measures) were identified, a meta-analysis was conducted to generate a pooled estimate of the effects. Review Manager software (The Cochrane Collaboration 2008, Copenhagen) was used to develop a random-effects model and derive the pooled estimates and the associated 95% confidence intervals (CIs). The rate ratio was used to evaluate the exacerbation rates per patients per year, or during the follow-up. Risk ratios were used to estimate the dichotomous outcomes, such as death and safety. Mean differences (MDs) were used for continuous variables, such as the FEV 1 and SGRQ scores. For dichotomous outcomes, the summary risk ratios and 95% CIs were estimated; for continuous data, the summary MDs and 95% CIs were estimated. The degree of heterogeneity was evaluated with Q statistic generated from the χ 2 test. The proportion of statistical heterogeneity was assessed by I 2 measure. Heterogeneity was considered as significant when P-value was less than 0.10 or I 2 more than 50%.
Results
Study selection and characteristics
A total of 3,037 articles were identified following the initial search; however, only seven studies, [11] [12] [13] [14] [15] [16] [17] which fulfilled the inclusion criteria were included in the metaanalysis ( Figure S1 ). In all of the studies except one, 14 the risk of bias in each domain [11] [12] [13] [15] [16] [17] was classified as low risk ( Figure S2 and S3). All of the included studies were randomized, double-blind, multicenter studies, which were designed to compare the clinical efficacy and safety of single inhaler triple therapy with other treatments for adult patients with COPD (Table 1) . Three studies [11] [12] [13] used BDP/FOR/GB single inhaler triple therapy, three studies [14] [15] [16] used FF/UMEC/VI and one study 17 Figure 1 ). Single inhaler triple therapy was associated with a significantly lower risk of COPD hospitalization compared with LABA/LAMA dual therapy (risk ratio, 0.68, 95% CI, 0.59 to 0.79), and ICS/LABA dual therapy (risk ratio, 0.87, 95% CI, 0.76 to 1.00; Figure S10 ). However, no significant differences while comparing to single inhaler triple therapy and separate triple therapy (risk ratio, 1.18; 95% CI, 0.77 to 1.81; Figure S10 ).
Secondary outcomes
Change in FEV 1 was the secondary outcome of interest. Comparisons were made between single inhaler triple therapy and LABA/LAMA or ICS/LABA dual therapy and separate triple therapy in three, four, and two of the RCTs, respectively. Single inhaler triple therapy showed significant improvements in FEV 1 compared with LABA/ LAMA (MD, 0.03; 95% CI, 0.01 to 0.06, I 2 =72%) and ICS/LABA (MD, 0.10; 95% CI, 0.06 to 0.14, I 2 =94%) dual treatment. In contrast, no significant differences in FEV 1 were noted between single inhaler triple therapy and separate triple therapy (MD, 0.01; 95% CI, −0.01 to 0.03, I 2 =0%; Figure 2) . Improvements in quality of life were determined using SGQR scores. Patients taking single inhaler triple therapy reported significantly higher improvements in quality of life compared with those taking LABA/LAMA dual therapy (MD, −1.59; 95% CI, −2.22 to −0.96, I 2 =0%) 11, 15, 17 and ICS/LABA dual therapy (MD, −153; 95% CI, −2.23 to −0.84, I 2 =21%; Figure 3) . 13, [15] [16] [17] In contrast, no significant differences were noted between the quality of life scores of patients taking single inhaler triple therapy and Figure S5 ).
In terms of overall mortality, no significant differences were found between single inhaler triple therapy and the other treatment options (vs LABA/LAMA, risk ratio, 0.99; 95% CI, 0.44 to 2.27, I 2 =31%; vs ICS/LABA, risk ratio, 1.00; 95% CI, 0.53 to 1.89, I 2 =0%; vs separate triple therapy, risk ratio, 0.48; 95% CI, 0.18 to 1.28, I 2 =49%; Figure S6 ). For respiratory mortality ( Figure S7 ) and COPD mortality ( Figure S8 ), there was also no significant difference between single inhaler triple therapy and the other treatment options.
Adverse events
Single inhaler triple therapy was associated with a significantly higher risk of pneumonia compared with LABA/LAMA dual therapy (risk ratio, 1.38, 95% CI, 1.14 to 1.67, I 2 =0), but no significant differences were found when it was compared with ICS/LABA dual therapy (risk ratio, Figure S9 ). In addition, there were no significant differences observed between single inhaler triple therapy and the comparative treatments in regard to the risk of treatment emergent adverse events, serious adverse events, and cardiovascular events ( Figures  S10-12 ). In addition, there were no significant differences observed between single inhaler triple therapy and the comparative treatments in regard to the risk of treatment emergent adverse events, serious adverse events, and cardiovascular events (Figures S7-9 ).
Discussion
Guidance on the use of triple therapy with ICS/LABA and LAMA has been included in the COPD GOLD guidelines. 19 The recent introduction of triple therapy with ICS/LABA/LAMA in a single inhalerprovides a convenient option for COPD patients with symptoms, which are uncontrolled by dual therapy or who are at high The present meta-analysis compared seven RCTs and identified several significant findings. It was found that single inhaler triple therapy was associated with a significantly lower risk of moderate or severe COPD exacerbations compared with dual therapy (ICS/LABA or LABA/LAMA). In addition, single inhaler triple therapy can provide additional benefits in terms of changes in FEV 1 and SGQR compared with dual therapy. However, single inhaler triple therapy did not improve the overall mortality when compared with dual therapy. These findings are consistent with other recent meta-analyses. 20, 21 Zheng et al, revealed that triple therapy was associated with significantly lower rates of moderate or severe exacerbations compared with dual therapy with LABA/ LAMA (RR, 0.78, 95% CI, 0.70 to 0.88) and ICS/LABA (risk ratio 0.77, 95% CI, 0.66 to 0.91), while the trough FEV 1 and SGQR scores were favorable for triple therapy. Cazzola et al, 21 reported that ICS/LABA/LAMA triple therapy reduced the risk of exacerbation (relative risk: 0.70, 95% CI 0.53-0.94) and improved trough FEV 1 (MD, mL: +37.94, 95% CI 18.83 to 53.89) compared with LABA/LAMA dual therapy. However, the triple therapies that were compared with dual therapies in these other meta-analyses 20,21 included a mix of single inhaler triple therapy and separate triple therapies. Therefore, the effect of single inhaler triple therapy on the outcomes of advanced COPD patients remains unclear; this was the focus of the present study. Overall, the results of the present study suggest that the use of single inhaler triple therapy can help patients with advanced COPD achieve lower rates of moderate or severe exacerbations, as well as better lung function and improved quality of life compared with LABA/LAMA or ICS/LAMA dual therapy. The current study found that single inhaler triple therapy carried a higher risk of pneumonia compared with LABA/LAMA dual therapy. However, there were no significant differences observed for the risk of pneumonia between single inhaler triple therapy and ICS/LABA dual therapy or separate triple therapy. This finding is consistent with a previous study, 20 which reported a higher risk of pneumonia among triple therapy patients compared with LABA/LAMA dual therapy patients (relative risk, 1.53, 95% CI 1.25 to 1.87). These findings could be explained by the effect of ICS on the risk of pneumonia; it was demonstrated in the UPLIFT study 22 17 who enrolled 2011 GOLD B patients, with some 80% having no prior year exacerbations. Therefore, FF was doses in an older, sicker population for a year (the IMPACT population), 15 while BUD was tested in younger, healthier patients for five and a half months in the KRONOS population). 17 Further study is warranted to clarify this issue.
No significant differences were found between triple therapy in a single inhaler and separate inhalers in terms of all outcomes, including the rate of COPD exacerbation, changes in lung function and quality of life, and the risk of pneumonia and LRTIs. The similar effects observed between the two treatments are understandable as the medication and dosage used for triple therapy in a single inhaler and in separate inhalers are similar. However, all of the findings from the present analysis were extracted from enrolled RCTs, and patients in RCTs may follow the study design for inhaler use more accurately than can be expected in a real-life setting. Patients in the real world tend to have higher compliance when they use a single inhaler containing triple therapy compared with using multiple inhalers. 23 Further investigation is warranted to compare the efficacy of triple therapy in a single inhaler and separate inhalers in the real world. A major strength of the present meta-analysis was that only RCTs with a low risk of bias were included, and all of the studies had been published in the last three years. However, the present study also had several limitations. Although most of the studies only enrolled patients with FEV 1 <50% and a previous history of COPD exacerbations, some of the studies did not. In addition, the patients included in the analysis used different LAMA/LABA and ICS from different devices and in different dosing regimens. Moreover, the number of enrolled RCTs were limited in this meta-analysis, particularly because each had unique treatment arm comparisons (a few vs components only two trials vs open triples), and the head-to-head trials open vs single inhaler triple were limited to just over 1,000 patients. All these factors may affect the heterogeneity of the meta-analysis.
Conclusions
The current meta-analysis indicated that the use of single inhaler triple therapy for COPD patients can result in a lower rate of moderate or severe exacerbations of COPD, as well as improved lung function and quality of life compared with LABA/LAMA or ICS/LABA dual therapy. However, triple therapy did not reduce the patient's overall mortality. In addition, they may increase their risk of pneumonia in comparison with LABA/LAMA dual therapy. The outcomes of the COPD patients were not affected by whether the triple therapy was administered in a single or separate inhalers.
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